Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ~7% of human malignancies and ~60% of melanomas(1). Early clinical experience with a novel class I RAF-selective inhibitor, PLX4032, demonstrated an unprecedented 80% anti-tumour response rate among patients with B-RAF(V600E)-pos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nazarian, Ramin, Shi, Hubing, Wang, Qi, Kong, Xiangju, Koya, Richard C., Lee, Hane, Chen, Zugen, Lee, Mi-Kyung, Attar, Narsis, Sazegar, Hooman, Chodon, Thinle, Nelson, Stanley F., McArthur, Grant, Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3143360/
https://ncbi.nlm.nih.gov/pubmed/21107323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09626
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars